Does a supermarket chain abuse its dominant position by impeding competitors form purchasing plots of land to build supermarkets ?

According to the Italian Competition Authority (ICA), this may be so. Following a complaint filed by a supermarket chain, Esselunga, the Italian Competition Authority (ICA) has opened investigations into two foreclosing conducts affecting retail markets. In the first case (A437) the ICA considered the conduct carried out by UniCoop Tirreno (UCT). UCT has a dominant position in the market for supermarkets and hypermarkets in the Tuscany province of Livorno. Here there exists high entry barriers due to the dearth of land available for the construction of shopping centers. A further entry barrier is the need for an obtain an authorization from the public administration before taking up commercial activities.

The Municipality of Livorno had awarded a developer an authorization to build a supermarket. Esselunga offered to buy the piece of land where the construction of the supermarket was authorized. Yet the developer sold the land to UCT, though its offer was lower than that submitted by Esselunga. Considering that UCT already operated two supermarkets close to this area, the ICA took the view that the only reason why UCT bought the plot of land was to impede Esselunga from entering the market.

The second investigation (A437B)is about two conducts put in place by COOP Estense (CE) to the detriment of Esselunga in the province of Modena. In 2000 Esselunga bought a share of a rundown area within the Municipality of Modena at the time when the Municipality was consider to redevelop that area. Some years later, CE bought a small share in the area paying much higher price that the effective value of it. Then, CE objected to the approval of the redevelopment plan by the local authorities. And then, the Municipality of Modena changed the destination of the area, thereby depriving Esselunga of the possibility to build there a supermarket. By the second conduct, CE sent the Municipality of Vignola, a letter by which it proposed to contribute to the welfare of the inhabitants of Vignola by helping building a school. The letter was sent ater the Mayor of Vignola convened a meeting to sign a contract with Esselunga for the construction of a supermarket. Unsurprisingly, the mayor withdrew the proposal made to Esselunga, which, as a result, could not build its supermarket. CE, on the other hand, have never realized any infrastructure in Vignola.

The ICA concluded that these conduct were part of a complex strategy of CE aimed at encumbering the administrative procedure for the grant of authorization to take up new commercial activities. The likely effects of that was to impede or frustrate the entry of a competitor in the market.

The common element in these conducts is that they are aimed at foreclosing a competitor by impeding it from having access to what is a finite resource in retail markets due to licensing and planning laws: land to build supermarkets. In one case, the only reason why the dominant firm bought a piece of land was that it would have been otherwise purchased by its competitor, Esselunga. As for the second case, the acquisition of land by the dominant player was instrumental in having a stand to administrative procedure having as object the grant of planning permissions to competitors. Therefore, the dominant firm had strategically exercised its right within these procedures to the effect that eventually the acting authority did not grant such permission to competitors.

Comments

Post a Comment

Popular posts from this blog

Aspen: The Italian Competition Authority fines a generic manufacturer of drugs for excessive pricing

By the decision made on 29 September 2016 in Aspen [i] , the Italian Competition Authority (ICA) has imposed a fine of more than EUR 5 million on the Aspen group (Aspen), a South African manufacturer of generic drugs. Aspen violated Article 102 TFEU by imposing excessive prices for the supply of the so-called ‘Cosmos drugs’. These drugs included Leukeran, Alkeran, Purinethol and Tioguanine, which included the active principles of chlorambucil, melphalan, mercaptopurine and tioguanine, respectively. All these drugs were used to treat cancer pathologies and included in a wider package of pharmaceutical products, whose marketing rights had been purchased by Aspen from the originator GlaxoSmithKline (GSK) in 2009. Aspen had a dominant position in the relevant product markets for the commercialization of anti-cancer drugs manufactured using the active principles of alkeran, leukeran, purinethol and tioguanine. It had the only one market authorization for the sale of drugs and potential
Read more

Geographical allocation of turnover in aviation mergers: What the European Commission recently hold

The European Merger Control Regulation (ECMR) stipulates that only concentrations with a European dimension fall within the regulatory jurisdiction of the European Commission to review. A concentration is presumed to have such a dimension when it meets the financial threshold in Article 1 of the ECMR. To this end, it is necessary to calculate the turnover generated by the merging parties within the Community or in one or more member states. However, the geographical allocation of the turnover required by Article 1 for the purpose to establish the Commission’s jurisdiction can be a tricky issue in case of mergers between undertakings with a cross-border activity such airliners. In fact, the activities of airlines span several countries as they typically operate flights and sell tickets in many national markets. Recently, the Commission has dealt with the issue at length in the Ryanair/Aer Lingus case. It identified three possible methodologies for geographical allocation of turnover: -
Read more

The Italian Competition Authority opens an investigation into an alleged refusal to deal

Industria Chimica Italiana (ICE) is the dominant player in the market for the production and sale of cholic acid that is an input for the preparation of an active principle, ursodeoxycholic acid or udca, used in the pharmaceutical industry. The udca is marketed by an ICE subsidiary, Prodotti Chimici e Alimentari  (PCA),  and by RGR. RGR filed a complaint with the Italian Competition Authority (ICA) reporting that ICE would have abused its dominant position in many ways. The ICA then opened an Article 102 TFEU investigation against PCA ( Case A473 RGR v PCA ). ICE has been supplying RGR with cholic acid since long. However, starting from 2009 when it bought PCA, ICR has progressively increased the prices applied on RGR for the supplies of cholic acid. The ICE price increases had no justification, and in any event they did not depend on a rise in the production costs incurred by ICE. Moreover, RGR may not shift its requirements to other suppliers. There exist only two other producers
Read more